Bayer/Schering’s Complementary Portfolios Include Focus On Oncology
Executive Summary
Bayer does not expect to divest any pharmaceutical products following the acquisition of Schering AG, CEO Werner Wenning said March 24 during a briefing outlining the planned merger
You may also be interested in...
Merck KGaA Strengthens Its Biotech Presence With Serono Acquisition
Merck KGaA's acquisition of Serono, Europe's leading biotechnology company, will enhance the German drug maker's position in biologics with a portfolio generating over $2 bil. in sales in the segment
Merck KGaA Strengthens Its Biotech Presence With Serono Acquisition
Merck KGaA's acquisition of Serono, Europe's leading biotechnology company, will enhance the German drug maker's position in biologics with a portfolio generating over $2 bil. in sales in the segment
AstraZeneca Rides Wave Of Crestor Data; Is Pfizer Facing Lipitor Wipeout?
Wall Street appears to feel that AstraZeneca has weathered the run up to the launch of generic statins far better than Pfizer